---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-22-000017"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2022-04-20T23:59:59+00:00"
generated_at: "2026-06-26T06:08:32.296978+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics CFO Laura Clague to retire; Christopher Cline named successor effective Aug 31, 2022

## Summary
- Laura Clague steps down as CFO on August 31, 2022 (or earlier if mutually agreed).
- Christopher Cline, current SVP Investor Relations & Corporate Communications, appointed CFO on that date.
- Clague remains employee through transition until March 31, 2023 at reduced base salary of $330,000 (70% of $471,000).
- Clague eligible for 2022 bonus at 50% target and pro-rata 2023 bonus at 40% target; equity continues vesting.
- Transition requires Clague to sign a general release on termination date.

## SEC filing metadata
- accession: 0001438533-22-000017
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2022-04-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/tvtx-20220419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-22-000017
- JSON: https://secwatch.observer/filing/0001438533-22-000017.json
- Plain text: https://secwatch.observer/filing/0001438533-22-000017.txt

## Key facts
- Executive change
  Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of the Officer Resignation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm
- Executive change
  Laura Clague retired as Chief Financial Officer at Travere Therapeutics, Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.